Arthritis & Rheumatism, Volume 62,
November 2010 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Atlanta, Georgia November 6-11, 2010.


Chemerin Levels Are Increased in Rheumatoid Arthritis Patients Who Smoke, Correlate with Disease Activity, and Decrease after Adalimumab Treatment.

Herenius2,  Marieke, Lebre3,  Cristina, Oliveira3,  Ana, Wijbrandts3,  Carla, Gerlag3,  Daniëlle, Tak1,  Paul P.

Academic Med Ctr/Univ of Amsterdam, Amsterdam, The Netherlands
Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Utrecht, The Netherlands
Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Background:

Chemerin is a recently discovered chemokine that modulates chemotaxis and activation of dendritic cells and macrophages. The expression of chemerin in rheumatoid synovial tissue strongly suggests involvement of chemerin in the migration/accumulation of dendritic cells and macrophages in the inflamed joint. Furthermore, we have recently shown in synovial biopsy explant cultures that chemerin levels are upgulated by TNF-a and that chemerin can induce TNF-a. Elevated chemerin levels have also been related to dyslipidemia and hypertension in obesity, thereby linking it to the metabolic syndrome.

Objective:

To explore the role of chemerin in rheumatoid arthritis (RA) in relationship to known cardiovascular risk factors and to evaluate the effects of anti-TNF treatment on serum levels of chemerin.

Methods:

49 patients with active RA (disease activity score evaluated in 28 joints (DAS28)) >=3.2) were started on adalimumab therapy (40 mg subcutaneously every other week). Blood was drawn from patients while fasting at baseline and 16 weeks after the initiation of therapy. Chemerin levels were measured by ELISA. Known risk factors for cardiovascular disease were determined at baseline.

Results:

Baseline chemerin levels correlated with DAS28 and ESR (r=0.38, p=0.007 and r=0.40, p=0.005, respectively). Of interest, we found chemerin levels to be significantly higher in current smokers (n=9, median 162ng/ ml, IQR 159–168 ng/ml) than non-smokers (n=33, median 143 ng/ml, IQR 130–169 ng/ml, p=0.03). Baseline chemerin levels were not related to sex, age, BMI, serum lipid levels (TC, HDL, LDL, TG, Apo A-I, Apo B, Lp(a))or cardiovascular events in the medical history. After 16 weeks of adalimumab treatment there was a significant reduction of DAS28, ESR, CRP (p<0.001, p<0.001, and p<0.001, respectively) associated with a reduction of serum levels of chemerin from 152 ng/ml (±34 ng/ml) to 141 ng/ml (±29 ng/ml) (p=0.025).

Conclusions:

Levels of chemerin are related to disease activity and reduce after adalimumab treatment. Interestingly, smoking might increase levels of chemerin, a potent chemoattractant for dendritic cells and macrophages, promoting clinical signs and symptoms of RA and perhaps also the metabolic syndrome.

To cite this abstract, please use the following information:
Herenius, Marieke, Lebre, Cristina, Oliveira, Ana, Wijbrandts, Carla, Gerlag, Daniëlle, Tak, Paul P.; Chemerin Levels Are Increased in Rheumatoid Arthritis Patients Who Smoke, Correlate with Disease Activity, and Decrease after Adalimumab Treatment. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :1507
DOI: 10.1002/art.29273

Abstract Supplement

Meeting Menu

2010 ACR/ARHP